key: cord-0783085-udxjt87a authors: Cataldo, Maria Adriana; Tetaj, Nardi; Selleri, Marina; Marchioni, Luisa; Capone, Alessandro; Caraffa, Emanuela; Di Caro, Antonino; Petrosillo, Nicola title: INCIDENCE OF BACTERIAL AND FUNGAL BLOODSTREAM INFECTIONS IN COVID-19 PATIENTS IN INTENSIVE CARE: AN ALARMING “COLLATERAL EFFECT” date: 2020-10-29 journal: J Glob Antimicrob Resist DOI: 10.1016/j.jgar.2020.10.004 sha: e09a81fa65c2fb17837080ea131b43e0c3a0bac5 doc_id: 783085 cord_uid: udxjt87a • COVID-19 patients have an exaggerated risk of acquiring BSI during ICU stay; • The incidence of ICU-acquired BSI in COVID-19 patients is higher than that reported in European ICUs in the pre-COVID-19 period; • The commonest etiologic agents of BSI were intestinal commensals. • A high rate of acquisition of VRE colonisation was observed. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Several issues related to the COVID-19 epidemic are starting to cause concern including the occurrence of bacterial and fungal infections, the plausible crisis of antimicrobial stewardship programs and an increase in antimicrobial resistance [1] [2] [3] . The real extent of these issues is poorly known due to the lack of ad hoc studies. In order to assess the incidence of bacterial and fungal bloodstream infections (BSIs) in COVID-19 patients in Intensive Care, we performed a retrospective cohort study including COVID-19 adult patients hospitalised in intensive care unit (ICU) from March 1 st to April 15 th 2020 at the National Institute for Infectious Diseases, Rome, Italy. In the ICU, infection prevention and control measures during health care of COVID-19 patients were applied according to the WHO recommendations [4] ; moreover measures for preventing the transmission of multi-drug resistant (MDR) bacteria were applied according to local protocols issued on the basis of international guidelines [5] [6] . The incidence of BSIs/10 000 ICU days was calculated including only the first episode of BSI. Subsequent BSI acquired after the first episode of BSI were also collected. Aetiology of BSI and susceptibility patterns of the isolates were recorded. Rate of BSIs in patients admitted to our ICU in the first 6 months of the previous year, were obtained. Results of surveillance samples of rectum to detect colonisation by MDR organisms were also collected. Finally, the mortality during ICU hospitalization was recorded. During the study period, 57 patients were admitted at our ICU. Forty-one were males (72%), the mean age (± standard deviation, SD) was 62 ± 13 years. The mean length of hospitalization (± SD) before ICU admission was 8 ± 8 days. Fifty-two patients (91%) had a central venous catheter indwelled and 48 (84%) were on mechanical invasive ventilation. Fiftysix patients (98%) were exposed to antibiotics in the 30 days before study inclusion; administered antibiotics were mainly an association of beta-lactam and macrolide. Regarding J o u r n a l P r e -p r o o f the treatment of severe COVID-19, 42 patients (74%) were exposed to corticosteroids and 26 (46%) to interleukin-6 blockers; all included patients received antivirals in the 30 days before the study inclusion, mainly lopinavir/ritonavir associated with hydroxychloroquine. BSIs occurred in 49% of them (28/57) with an incidence rate of 373 per 10,000 patientdays. The mean time from the ICU admission to the occurrence of BSI was 13 days ± 7 (range 3-34 days). The commonest isolated agents included Enterococcus spp (11 cases) and Pseudomonas spp (8 cases); Candida spp was isolated in 5 cases; in 3 patients more than one agent was isolated from blood cultures. Table 1 shows the etiological agents isolated from blood cultures of 28 patients with BSI. Seven out of 28 patients (25%) acquired a subsequent BSI during the ICU stay, due to the following etiologic agent: P. aeruginosa (2 cases), C. incospicua (1), C. parapsilosis (1), Regarding antimicrobial resistance pattern of the blood isolates, among Enterococci (except for E. gallinarum that are intrinsically vancomycin-resistant), two E. faecium isolates (2/10, 20%) were resistant to vancomycin (VRE). Among Pseudomonas spp strains, four (4/10, 40%) were resistant to piperacillin/tazobactam and one to carbapenems (1/10, 10%). Regarding Enterobacterales, two isolates were extended-spectrum-β-lactamase producing (2/6, 33%); no resistance to carbapenems was observed among these isolates. All Candida spp isolates were susceptible to echinocandins, only 1 (C. parapsilosis) was resistant to fluconazole. Overall, 17 patients (30%) were colonised by VRE (all E. faecium), 12 patients acquired VRE during ICU hospitalization whereas five were already colonised at ICU admission. No patient acquired colonisation by other MDR organisms. Three VRE colonised patients acquired BSI due to E. faecium; comparing the susceptibility pattern of these bacterial strains, in two patients the strains isolated from blood cultures were phenotypically similar to those isolated from rectal swab. No difference in mortality rate was observed among patients with and without BSI; the overall ICU mortality rate was 32% (18/57). Regarding historical data, in the first 6 months of the previous year 75 patients were admitted at our ICU. Blood cultures performed during ICU admission yielded a recognized bacterial or fungal pathogen in 10 patients, with a prevalence of BSIs of 13% (10/75). The prevalence of intestinal colonisation by VRE was 15% (11/75); no blood cultures yielded VRE. Our findings evidenced an exaggerated risk of acquiring bacterial and fungal BSIs among critically ill patients with COVID-19 in ICU, namely an incidence almost 20 times higher than the incidence reported in European ICUs [7] . In the pre-COVID-19 period, the prevalence of BSI in patients staying in our ICU was 3.8 times lower than the prevalence observed in our ICU COVID-19 patients. Pseudomonas aeruginosa + Enterococcus faecium 1 Enterococcus faecalis 3 Klebsiella aerogenes + Enterococcus faecium 1 Klebsiella pneumoniae 1 Enterobacter cloacae 1 Enterococcus casseliflavus/gallinarum 2 Candida glabrata + Candida parapsilosis 1 Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing Involving Antimicrobial Stewardship Programs in COVID-19 Response Efforts: All Hands on Deck Bacterial and fungal infections in COVID-19 patients: A matter of concern Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed: interim guidance. World Health Organization Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units